Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SHBG | P04278 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14651997 | 0.95 | SHBG (0.44) | TSHRSHBGEPHX2 | |
| SCHEMBL2683318 | 0.95 | SHBG (0.44) | TSHRSHBGEPHX2 | |
| SCHEMBL4845915 | 0.90 | TSHR (0.47) | TSHRSHBG | |
| SCHEMBL6757968 | 0.89 | SHBG (0.52) | TSHRSHBGEPHX2 | |
| SCHEMBL766799 | 0.89 | SHBG (0.52) | TSHRSHBGEPHX2 | |
| SCHEMBL42884 | 0.89 | SHBG (0.52) | TSHRSHBGEPHX2 | |
| SCHEMBL140725 | 0.81 | — | — | |
| SCHEMBL24256310 | 0.80 | DPP4 (0.39) | TSHRSHBG | |
| SCHEMBL4840491 | 0.80 | TSHR (0.43) | TSHRSHBGCA12CA1CA2 | |
| SCHEMBL4892144 | 0.80 | SHBG (0.44) | TSHRSHBGEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010584-A | Method for synthesizing arone by oxidizing benzyl tertiary carbon broken bond under catalysis of iron | 南京师范大学 | 2022-09-06 | — | — | CN | disclosed |
| EP-1710223-B1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7332632-B2 | Method for producing aldehyde compound or ketone compound by using microreactor | Ubē Industries, Ltd. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | UBE INDUSTRIES, LTD., A CORPORATION OF JAPAN (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1710223-A1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | Ube Industries, Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | ADH1C, ADH1A, ALDH1A1 | TSHR 2363/4885SHBG 4583/4885EPHX2 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.